Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06159790 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT06159790 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 218 participants.
The verdict
NCT06159790, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.
Interventions
- DRUG GME751
- DRUG Keytruda-EU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2026-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06159790
The ClinicalTrials.gov registry entry for NCT06159790 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GME751 is the first listed.
NCT06159790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06159790 about?
NCT06159790 is a clinical study titled "A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)". The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.
What is the current status of trial NCT06159790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2024-04-29. Estimated completion is 2026-03-16.
What interventions are being tested in trial NCT06159790?
The interventions under investigation include: GME751 (DRUG), Keytruda-EU (DRUG).
Who is sponsoring clinical trial NCT06159790?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.